ArticleJournal of pain research2025
Lipid Transporter ABCA1 in Diabetic Polyneuropathy: Potential Mediation by Circulating Metabolites.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic polyneuropathy (DPN) is a complication of diabetes characterized by peripheral sensory deficits or neuropathic pain. Emerging evidence suggests that DPN is associated with dyslipidemia. Probucol has shown promise in the treatment of diabetes and alleviation of neuropathic pain. However, the influence of probucol on DPN or dyslipidemia incidence is unclear. The study examined the mediating effects of circulating metabolites on the relationship between probucol target gene ATP-binding cassette subfamily A member 1 (ABCA1) and DPN. Methods: A positive control analysis was done on low density lipoprotein (LDL) to validate genetic instruments. A two-step Mendelian randomization (MR) study was conducted to assess the correlation between the probucol target gene ABCA1 and DPN, focusing on the mediation effects of circulating metabolites connecting them. MR analysis was mainly estimated using Inverse-variance weighted (IVW) and MR-Egger regression conducting SNP heterogeneity and sensitivity analysis. Results: Predicted based on genetics, the ABCA1 gene is associated with increased risk of LDL and four circulating metabolites. The direct effect of the Probucol target gene ABCA1 on DPN was 0.3006, and the mean diameter for high-density lipoprotein (HDL) particles, total cholesterol in medium LDL, triglycerides in medium very low-density lipoprotein (VLDL), and free cholesterol in very large HDL had partial mediating effects on the association between ABCA1 and DPN incidence. Conclusion: This study supports an association between genetically predicted Probucol target ABCA1, circulating metabolites, and DPN. Our observations indicate a direct effect of ABCA1 on DPN and a mediating pathway through four blood circulation metabolites. Our findings offer genetic evidence for the mechanisms of Probucol in preventing, alleviating, and treating DPN pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.